Evidence map›Paper›PMID 27591861›Full record

ArticleJournal of cancer research and clinical oncology2016

Epothilone B induces apoptosis and enhances apoptotic effects of ABT-737 on human cancer cells via PI3K/AKT/mTOR pathway.

Yang-Ling Li, Jiao Sun, Xiu Hu, Yi-Ni Pan, Wei Yan, Qing-Yu Li, Fei Wang, Neng-Ming Lin, Chong Zhang

Open access · greenAbstract read
In one paragraph

Article in Journal of cancer research and clinical oncology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
0.8field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 17 citations in OpenAlex.

  1. Article
  2. Article
  3. BH3-mimetics: recent developments in cancer therapy.Journal of experimental & clinical cancer research : CR · 2021
    Review
  4. B Cell Lymphoma 2: A Potential Therapeutic Target for Cancer Therapy.International journal of molecular sciences · 2021
    Review
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Yang-Ling LiDepartment of Clinical Pharmacology, Hangzhou First People's Hospital, Nanjing Medical University, No. 261 Huansha Road, Hangzhou, 310006, Zhejiang, China.
Jiao SunDepartment of Pharmacy, Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China.
Xiu HuSchool of Medicine, Zhejiang University City College, No. 51 Huzhou Street, Hangzhou, 310015, Zhejiang, China.
Yi-Ni PanSchool of Medicine, Zhejiang University City College, No. 51 Huzhou Street, Hangzhou, 310015, Zhejiang, China.
Wei YanDepartment of Clinical Pharmacology, Hangzhou First People's Hospital, Nanjing Medical University, No. 261 Huansha Road, Hangzhou, 310006, Zhejiang, China.
Qing-Yu LiDepartment of Clinical Pharmacology, Hangzhou First People's Hospital, Nanjing Medical University, No. 261 Huansha Road, Hangzhou, 310006, Zhejiang, China.
Fei WangDepartment of Clinical Pharmacology, Hangzhou First People's Hospital, Nanjing Medical University, No. 261 Huansha Road, Hangzhou, 310006, Zhejiang, China.
Neng-Ming LinDepartment of Clinical Pharmacology, Hangzhou First People's Hospital, Nanjing Medical University, No. 261 Huansha Road, Hangzhou, 310006, Zhejiang, China. lnm1013@163.com.
Chong ZhangSchool of Medicine, Zhejiang University City College, No. 51 Huzhou Street, Hangzhou, 310015, Zhejiang, China. zhangchong@zucc.edu.cn.
Hangzhou First People's Hospital · CNZhejiang University · CNZhejiang Cancer Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeEpothilone B and its derivatives are tested in multiple clinical trials. Epothilone B induces neurotoxic effect in clinical trials; however, low-dose epothilone B regimen can promote neuroprotection and neurogenesis. Thus, the study of new combination chemotherapy regimen incorporating low-dose epothilone B with other chemotherapeutic agents might help to develop epothilone B-based approaches to cancer treatment and avoid the neurotoxicity of epothilone B.

methodsCell proliferation was assessed by SRB cell viability assay. Apoptosis was analyzed by propidium iodide (PI) staining. Mitochondrial membrane depolarization was evaluated using JC-1 staining. The expression of proteins was detected by western blotting.

resultsIn this study, we demonstrated that the combination of ABT-737 and low-dose epothilone B showed synergistic anti-proliferation effects on human cancer cells. In addition, epothilone B + ABT-737 synergy was through mitochondria-mediated apoptosis pathway. Furthermore, combination treatment markedly induced the activation of caspase-3 and the cleavage of PARP. The activation of PI3K/Akt/mTOR pathway is associated with resistance to epothilone B. Our data showed that epothilone B plus ABT-737 resulted in a blockade of the PI3K/AKT/mTOR signaling pathway.

conclusionsThese data indicate that ABT-737 may be a pertinent sensitizer to epothilone B, and the strategy of combining epothilone B with ABT-737 appears to be an attractive option for overcoming the resistance and neurotoxicity of epothilone B.

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsApoptosisBiphenyl CompoundsCell Line, TumorCell ProliferationDrug SynergismEpothilonesHumansMitochondriaNeoplasmsNitrophenolsPhosphatidylinositol 3-KinasesPiperazinesProto-Oncogene Proteins c-aktSignal TransductionSulfonamidesABT-737Biphenyl Compoundsepothilone BEpothilonesMTOR protein, humanNitrophenolsPhosphatidylinositol 3-KinasesPiperazinesProto-Oncogene Proteins c-aktSulfonamidesTOR Serine-Threonine KinasesABT-737ApoptosisEpothilone BNeurotoxicityPI3K/Akt/mTOR

Identifiers

PMID27591861
PMCPMC11819010
OpenAlexW2507889921

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.